Sunday, November 11, 2018 2:35:13 PM
Also I think existing Beta radioisotope systems utilize a metallic bead or rod system for the y90 delivery to the tumor from what I have found in my research. The metals end up remaining behind in the patient complicating future MRI's, etc and can "travel" throughout the patients body causing ongoing mischief that is considered acceptable to someone who can say that at least they are in cancer remission.
I think Isopet / Radiogel (our unique device) embeds the y90 molecules in an aqueous liquid (also already fda approved) that has been tuned to turn to gel at body temperature and remain gel for the 64 hours needed to get 90% of the Y90 decayed while exposed to the tumor. Our device inserts our liquid radioisotope into the interstitial spaces of the tumor itself flooding between the cancer cells and further isolating them from each other when in gel mode yet being contained within the tumor.
I have read articles on some y90 treatments where the little metal y90 infused spikes are used to coat the tumor... The tumor coating can allow the y90 to damage neighboring healthy tissues, whereas our method being contained "in tumor" further reduces healthy tissue damage risks.
Our device seems to me based on my reading to cost less, improve the radiation yield to tumor, reduce the exposure risks, and leaves NO metallic residues in patient post treatment. Human trials would indicate highest safe radiation dosages and any morbidity problems associated with the inoperable tumor detritus as far as the human body ability to absorb and void the destroyed tumor(s) with or without aid.
Does that help?
-Go RDGL$$$
Recent RDGL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 06:28:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 12/07/2023 05:15:10 AM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 07:22:21 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM